AAPL343.58-4.14 (-1.19%) ▼|ABBV285.94+0.30 (+0.11%) ▲|ABT103.73+0.03 (+0.03%) ▲|ACN243.84-5.53 (-2.22%) ▼|ADBE254.51-9.31 (-3.53%) ▼|AMAT391.89+14.65 (+3.88%) ▲|AMD533.06+16.27 (+3.15%) ▲|AMGN441.29+2.03 (+0.46%) ▲|AMT189.23+0.26 (+0.14%) ▲|AMZN249.00+1.00 (+0.40%) ▲|AVGO331.01+9.33 (+2.90%) ▲|AXP313.88+0.66 (+0.21%) ▲|BA188.99+0.64 (+0.34%) ▲|BAC50.74+0.18 (+0.36%) ▲|BKNG151.78-4.05 (-2.60%) ▼|BLK1,131.27+13.02 (+1.16%) ▲|BMY61.31-0.17 (-0.28%) ▼|BNY147.57+2.93 (+2.03%) ▲|BRK-B545.93+3.74 (+0.69%) ▲|C121.64+1.02 (+0.85%) ▲|CAT695.62+10.25 (+1.50%) ▲|CL92.58-1.47 (-1.56%) ▼|CMCSA21.95-0.75 (-3.28%) ▼|COF202.91+1.57 (+0.78%) ▲|COP151.54+0.74 (+0.49%) ▲|COST1,000.76-2.56 (-0.26%) ▼|CRM244.61-3.96 (-1.59%) ▼|CSCO110.53+4.03 (+3.78%) ▲|CVS92.17-1.31 (-1.40%) ▼|CVX232.52-0.70 (-0.30%) ▼|DE639.90-6.26 (-0.97%) ▼|DHR231.88+1.38 (+0.60%) ▲|DIS110.22-2.30 (-2.04%) ▼|DUK124.33-0.65 (-0.52%) ▼|EMR162.18+0.59 (+0.36%) ▲|FDX301.02+2.30 (+0.77%) ▲|GD354.67+5.31 (+1.52%) ▲|GE286.40+0.76 (+0.27%) ▲|GEV857.99+42.99 (+5.27%) ▲|GILD158.38+2.34 (+1.50%) ▲|GM76.24+0.32 (+0.42%) ▲|GOOG314.78-2.50 (-0.79%) ▼|GOOGL317.99-2.22 (-0.69%) ▼|GS897.99+22.31 (+2.55%) ▲|HD316.90-2.93 (-0.92%) ▼|HON219.75-1.40 (-0.63%) ▼|IBM252.76-0.80 (-0.32%) ▼|INTC91.85+4.89 (+5.62%) ▲|INTU335.36-8.04 (-2.34%) ▼|ISRG448.02-4.27 (-0.94%) ▼|JNJ265.55+1.74 (+0.66%) ▲|JPM334.93+3.35 (+1.01%) ▲|KO92.57-0.14 (-0.15%) ▼|LIN510.18+1.35 (+0.27%) ▲|LLY1,280.34+6.88 (+0.54%) ▲|LMT631.11+26.93 (+4.46%) ▲|LOW196.94-1.74 (-0.88%) ▼|LRCX239.61+9.51 (+4.13%) ▲|MA614.10-9.51 (-1.52%) ▼|MCD249.22+0.76 (+0.31%) ▲|MDLZ62.71-1.10 (-1.72%) ▼|MDT94.30-1.11 (-1.16%) ▼|META635.86-6.76 (-1.05%) ▼|MMM172.44-1.02 (-0.59%) ▼|MO73.56-0.76 (-1.02%) ▼|MRK140.96-4.32 (-2.97%) ▼|MS185.38+5.89 (+3.28%) ▲|MSFT531.29+6.78 (+1.29%) ▲|MU914.17+36.62 (+4.17%) ▲|NEE82.14+0.04 (+0.04%) ▲|NFLX63.11-2.74 (-4.16%) ▼|NKE37.61+0.31 (+0.82%) ▲|NOW156.43-2.53 (-1.59%) ▼|NVDA216.26+5.30 (+2.51%) ▲|ORCL125.99-0.17 (-0.13%) ▼|PEP135.20-0.57 (-0.42%) ▼|PFE29.78-0.25 (-0.83%) ▼|PG159.00-2.02 (-1.25%) ▼|PLTR199.36+2.61 (+1.32%) ▲|PM201.78+2.31 (+1.16%) ▲|QCOM178.50+2.59 (+1.47%) ▲|RTX197.18+6.17 (+3.23%) ▲|SBUX102.05+1.25 (+1.24%) ▲|SCHW89.81-0.78 (-0.86%) ▼|SO92.36-0.53 (-0.57%) ▼|SPG212.39+0.76 (+0.36%) ▲|T20.92-0.02 (-0.07%) ▼|TMO680.03+6.21 (+0.92%) ▲|TMUS145.09-1.46 (-0.99%) ▼|TSLA395.16+22.94 (+6.16%) ▲|TXN291.80+7.11 (+2.50%) ▲|UBER66.33-0.37 (-0.55%) ▼|UNH411.11-6.98 (-1.67%) ▼|UNP294.93+2.06 (+0.70%) ▲|UPS100.08-0.98 (-0.97%) ▼|USB59.85+0.27 (+0.45%) ▲|V403.66-4.26 (-1.04%) ▼|VZ43.17-1.50 (-3.35%) ▼|WFC83.11+0.72 (+0.87%) ▲|WMT120.57+0.68 (+0.57%) ▲|XOM183.77+0.56 (+0.30%) ▲|AAPL343.58-4.14 (-1.19%) ▼|ABBV285.94+0.30 (+0.11%) ▲|ABT103.73+0.03 (+0.03%) ▲|ACN243.84-5.53 (-2.22%) ▼|ADBE254.51-9.31 (-3.53%) ▼|AMAT391.89+14.65 (+3.88%) ▲|AMD533.06+16.27 (+3.15%) ▲|AMGN441.29+2.03 (+0.46%) ▲|AMT189.23+0.26 (+0.14%) ▲|AMZN249.00+1.00 (+0.40%) ▲|AVGO331.01+9.33 (+2.90%) ▲|AXP313.88+0.66 (+0.21%) ▲|BA188.99+0.64 (+0.34%) ▲|BAC50.74+0.18 (+0.36%) ▲|BKNG151.78-4.05 (-2.60%) ▼|BLK1,131.27+13.02 (+1.16%) ▲|BMY61.31-0.17 (-0.28%) ▼|BNY147.57+2.93 (+2.03%) ▲|BRK-B545.93+3.74 (+0.69%) ▲|C121.64+1.02 (+0.85%) ▲|CAT695.62+10.25 (+1.50%) ▲|CL92.58-1.47 (-1.56%) ▼|CMCSA21.95-0.75 (-3.28%) ▼|COF202.91+1.57 (+0.78%) ▲|COP151.54+0.74 (+0.49%) ▲|COST1,000.76-2.56 (-0.26%) ▼|CRM244.61-3.96 (-1.59%) ▼|CSCO110.53+4.03 (+3.78%) ▲|CVS92.17-1.31 (-1.40%) ▼|CVX232.52-0.70 (-0.30%) ▼|DE639.90-6.26 (-0.97%) ▼|DHR231.88+1.38 (+0.60%) ▲|DIS110.22-2.30 (-2.04%) ▼|DUK124.33-0.65 (-0.52%) ▼|EMR162.18+0.59 (+0.36%) ▲|FDX301.02+2.30 (+0.77%) ▲|GD354.67+5.31 (+1.52%) ▲|GE286.40+0.76 (+0.27%) ▲|GEV857.99+42.99 (+5.27%) ▲|GILD158.38+2.34 (+1.50%) ▲|GM76.24+0.32 (+0.42%) ▲|GOOG314.78-2.50 (-0.79%) ▼|GOOGL317.99-2.22 (-0.69%) ▼|GS897.99+22.31 (+2.55%) ▲|HD316.90-2.93 (-0.92%) ▼|HON219.75-1.40 (-0.63%) ▼|IBM252.76-0.80 (-0.32%) ▼|INTC91.85+4.89 (+5.62%) ▲|INTU335.36-8.04 (-2.34%) ▼|ISRG448.02-4.27 (-0.94%) ▼|JNJ265.55+1.74 (+0.66%) ▲|JPM334.93+3.35 (+1.01%) ▲|KO92.57-0.14 (-0.15%) ▼|LIN510.18+1.35 (+0.27%) ▲|LLY1,280.34+6.88 (+0.54%) ▲|LMT631.11+26.93 (+4.46%) ▲|LOW196.94-1.74 (-0.88%) ▼|LRCX239.61+9.51 (+4.13%) ▲|MA614.10-9.51 (-1.52%) ▼|MCD249.22+0.76 (+0.31%) ▲|MDLZ62.71-1.10 (-1.72%) ▼|MDT94.30-1.11 (-1.16%) ▼|META635.86-6.76 (-1.05%) ▼|MMM172.44-1.02 (-0.59%) ▼|MO73.56-0.76 (-1.02%) ▼|MRK140.96-4.32 (-2.97%) ▼|MS185.38+5.89 (+3.28%) ▲|MSFT531.29+6.78 (+1.29%) ▲|MU914.17+36.62 (+4.17%) ▲|NEE82.14+0.04 (+0.04%) ▲|NFLX63.11-2.74 (-4.16%) ▼|NKE37.61+0.31 (+0.82%) ▲|NOW156.43-2.53 (-1.59%) ▼|NVDA216.26+5.30 (+2.51%) ▲|ORCL125.99-0.17 (-0.13%) ▼|PEP135.20-0.57 (-0.42%) ▼|PFE29.78-0.25 (-0.83%) ▼|PG159.00-2.02 (-1.25%) ▼|PLTR199.36+2.61 (+1.32%) ▲|PM201.78+2.31 (+1.16%) ▲|QCOM178.50+2.59 (+1.47%) ▲|RTX197.18+6.17 (+3.23%) ▲|SBUX102.05+1.25 (+1.24%) ▲|SCHW89.81-0.78 (-0.86%) ▼|SO92.36-0.53 (-0.57%) ▼|SPG212.39+0.76 (+0.36%) ▲|T20.92-0.02 (-0.07%) ▼|TMO680.03+6.21 (+0.92%) ▲|TMUS145.09-1.46 (-0.99%) ▼|TSLA395.16+22.94 (+6.16%) ▲|TXN291.80+7.11 (+2.50%) ▲|UBER66.33-0.37 (-0.55%) ▼|UNH411.11-6.98 (-1.67%) ▼|UNP294.93+2.06 (+0.70%) ▲|UPS100.08-0.98 (-0.97%) ▼|USB59.85+0.27 (+0.45%) ▲|V403.66-4.26 (-1.04%) ▼|VZ43.17-1.50 (-3.35%) ▼|WFC83.11+0.72 (+0.87%) ▲|WMT120.57+0.68 (+0.57%) ▲|XOM183.77+0.56 (+0.30%) ▲|
16.7 C
New York
Monday, October 26, 2026

Tag: science

Else Nutrition Applauds U.S. Government’s Historic Shift in Infant Formula Rules, Unlocking Path to Commercialize the World’s First Whole-Food, Dairy-Free Infant Formula

Else Nutrition Welcomes 3 Major Federal Developments that Could Unlock Market Access & Open the Door to the First Major Breakthrough in Infant Formula...

Aurora Spine Surpasses Milestone of 2,500 Procedures Using SiLO™ SI Joint Fusion System

CARLSBAD, CALIFORNIA, June 10, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a pioneer in innovative spinal solutions, proudly announces that its proprietary SiLO™ Sacroiliac (SI) Joint Fusion System has been successfully used in over 2,500 procedures across the United States. This major milestone underscores the company’s accelerating growth and increasing adoption of its minimally invasive technology by surgeons nationwide.

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically...

NANO Nuclear Appoints Former U.S. Secretary of Energy and 47th Governor of Texas Rick Perry as Chairman of its Executive Advisory Board

New York, N.Y., June 10, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that it has appointed Rick Perry, former Governor of Texas and the United States Secretary of Energy from 2017 to 2019, as the Chairman of its Executive Advisory Board.

Newton Golf Company Appoints Jeff Clayborne as Chief Financial Officer

Experienced Public Company Executive to Lead Financial Strategy and Support Newton’s Continued Growth
Experienced Public Company Executive to Lead Financial Strategy and Support Newton’s Continued Growth

/R E P E A T — Media advisory – Minister Joly and Petrina Gentile to discuss the future of the Canadian auto industry...

VAUGHAN, ON, June 9, 2025 /CNW/ - The Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions,...

VIAVI and Hanyang University Sign Memorandum of Understanding to Advance 6G Research

CHANDLER, Ariz., June 10, 2025 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ: VIAV) and Hanyang University, one of South Korea's leading academic institutions, today announced...

HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration

Tuebingen, Germany, June 10, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced that the first patient has been dosed in their Phase Ib clinical trial of its lead candidate HRX-215. The trial is evaluating the safety and efficacy of HRX-215, an orally available small-molecule inhibitor of MKK4, in patients undergoing partial liver resection due to liver metastases deriving from colorectal cancer. HXR-215 is designed to treat advanced-stage liver disease by increasing the regenerative capacity of hepatocytes. An initial data readout is planned for the second half of 2025.

Asia Tech x Singapore 2025 Recap

SINGAPORE, June 10, 2025 /PRNewswire/ -- At the recent ATxSummit, the apex event of Asia Tech x Singapore (ATxSG) 2025, organised by the Infocomm Media...

Pearson Redefines its Brand to Embrace the Future of Learning

New brand identity reflects learning as a core human need, essential for personal happiness and progress HONG KONG, June 10, 2025 /PRNewswire/ -- Pearson (FTSE: PSON.L), the...

ClavystBio and A*STAR Partner to Grow MedTech Ventures in Singapore

SINGAPORE, June 10, 2025 /PRNewswire/ -- ClavystBio, a life sciences investor and venture builder established by Temasek, and the Agency for Science, Technology and...

Heungkong, Panasonic and Tantron Unveil Breakthrough in Forest-Ecology-Inspired Indoor Bionic Technology

GUANGZHOU, China, June 10, 2025 /PRNewswire/ -- Heungkong Group, Panasonic Electric, and Tantron Technology have announced the mid-stage outcomes of their collaborative innovation, the...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsScience